DV
Dividend Vision

ALGS — Aligos Therapeutics Inc

Aligos Therapeutics Inc (ALGS)

Total return is -98.1% over the past 5.8 years, 239.9 points behind SPY at 141.8%. Its deepest 1-year drawdown was 69.3%.

Aligos Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for liver and viral diseases, with drug candidates including ALG-055009 for metabolic dysfunction-associated steatohepatitis and obesity, pevifoscorvir sodium for viral hepatitis, and ALG-097558 for coronavirus treatment. The company does not currently distribute dividends, as is typical for early-stage biotech firms focused on research and development. Aligos Therapeutics may appeal to investors seeking exposure to clinical-stage therapeutic development with a focus on unmet medical needs, though the company carries inherent risks associated with drug development and clinical trials.

ALGS key facts

Asset type
Stock
Asset class
Equity
Inception date
10/16/2020
Last close
$6.89
Market cap
$35,520,400
Average volume
66900.0
Beta
2.256
Payout ratio
0.0
Forward P/E
0.0
EPS
$-9.78